Guzmán Alonso

982 total citations · 1 hit paper
34 papers, 313 citations indexed

About

Guzmán Alonso is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Guzmán Alonso has authored 34 papers receiving a total of 313 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Guzmán Alonso's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Cancer Genomics and Diagnostics (6 papers). Guzmán Alonso is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Cancer Genomics and Diagnostics (6 papers). Guzmán Alonso collaborates with scholars based in Spain, United States and Germany. Guzmán Alonso's co-authors include Vivek Subbiah, Benjamin Solomon, Victoria Soldatenkova, Oliver Gautschi, Filippo de Braud, Daniel S.W. Tan, Tarun Puri, Keunchil Park, Pascale Tomasini and Scott Barker and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Nutrients.

In The Last Decade

Guzmán Alonso

29 papers receiving 306 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

2022 119 citations Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guzmán Alonso Spain	8	177	161	75	66	43	34	313
Benjamin Bonhomme France	8	131 0.7×	81 0.5×	44 0.6×	45 0.7×	35 0.8×	15	261
Allison Tyler United States	10	194 1.1×	220 1.4×	108 1.4×	149 2.3×	52 1.2×	23	393
Nikoletta Sidiropoulos United States	8	163 0.9×	114 0.7×	135 1.8×	76 1.2×	34 0.8×	21	336
Yoshiro Nakahara Japan	12	282 1.6×	255 1.6×	54 0.7×	55 0.8×	44 1.0×	42	414
Elif Bilgin Türkiye	12	124 0.7×	66 0.4×	85 1.1×	130 2.0×	53 1.2×	33	310
Minghan Jia China	10	206 1.2×	102 0.6×	127 1.7×	133 2.0×	28 0.7×	21	394
Geer Zhang China	6	165 0.9×	83 0.5×	58 0.8×	119 1.8×	133 3.1×	12	360
Kartik Konduri United States	8	260 1.5×	168 1.0×	34 0.5×	107 1.6×	36 0.8×	27	365
M.E. Gleave Canada	8	137 0.8×	183 1.1×	117 1.6×	172 2.6×	51 1.2×	22	413
Anne‐Katrin Zimmermann Switzerland	9	139 0.8×	91 0.6×	76 1.0×	118 1.8×	29 0.7×	11	337

Countries citing papers authored by Guzmán Alonso

Since Specialization

Citations

This map shows the geographic impact of Guzmán Alonso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guzmán Alonso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guzmán Alonso more than expected).

Fields of papers citing papers by Guzmán Alonso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guzmán Alonso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guzmán Alonso. The network helps show where Guzmán Alonso may publish in the future.

Co-authorship network of co-authors of Guzmán Alonso

This figure shows the co-authorship network connecting the top 25 collaborators of Guzmán Alonso. A scholar is included among the top collaborators of Guzmán Alonso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guzmán Alonso. Guzmán Alonso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alonso, Guzmán, et al.. (2025). Early generational and partisan divides in vaccine acceptance in USA during the COVID-19 pandemic. Health Promotion International. 40(6).

Harrington, Kevin J., Shigehisa Kitano, Valentina Gambardella, et al.. (2025). Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors. Future Oncology. 21(2). 195–200. 2 indexed citations

Mirallas, Oriol, Ana Carolina Ramos Moreno, Cristina Viaplana, et al.. (2025). Ultrasensitive ctDNA profiling to identify long-term survivors in phase I immunotherapy trials.. Journal of Clinical Oncology. 43(16_suppl). 2560–2560.

Melero, Ignacio, Maria J. de Miguel, Guillermo de Velasco, et al.. (2024). Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer.. Journal of Clinical Oncology. 42(16_suppl). 2513–2513. 2 indexed citations

Garralda, Elena, Guillermo de Velasco, Víctor Moreno, et al.. (2024). First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma.. Journal of Clinical Oncology. 42(16_suppl). 2505–2505. 5 indexed citations

El-Khoueiry, Anthony B., Elena Garralda, Andrés Cervantes, et al.. (2024). A phase I monotherapy dose escalation study of HFB301001, a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2531–2531. 1 indexed citations

Toledo, Rodrigo A., Oriol Mirallas, Ana Carolina Ramos Moreno, et al.. (2024). Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.. Journal of Clinical Oncology. 42(16_suppl). 2510–2510. 2 indexed citations

Heymach, John V., Nuria Kotecki, Hans Prenen, et al.. (2023). 665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation. Annals of Oncology. 34. S468–S468. 10 indexed citations

Calvo, Emiliano, Elena Garralda, Guzmán Alonso, et al.. (2023). 1030P Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors. Annals of Oncology. 34. S626–S626. 7 indexed citations

10.

Joerger, Markus, Emiliano Calvo, Heinz Läubli, et al.. (2023). Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for ImmunoTherapy of Cancer. 11(11). e007784–e007784. 15 indexed citations

11.

Alonso, Guzmán, C. Saura Manich, Carolina Ortiz, et al.. (2023). 538P Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials. Annals of Oncology. 34. S405–S406. 1 indexed citations

12.

Drilon, Alexander, Vivek Subbiah, Oliver Gautschi, et al.. (2022). Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. Journal of Clinical Oncology. 41(2). 385–394. 119 indexed citations breakdown →

13.

Ros, Javier, N. Saoudi Gonzalez, Francesc Salvà, et al.. (2022). Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies. Expert Opinion on Investigational Drugs. 31(3). 235–247. 4 indexed citations

14.

Drilon, A., Oliver Gautschi, Filippo de Braud, et al.. (2022). 27P Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC). Annals of Oncology. 33. S43–S43. 5 indexed citations

15.

Alonso, Guzmán, Javier Ros, Helena Verdaguer, et al.. (2021). 6P Circulating tumor DNA (ctDNA) next generation sequencing (NGS): Molecular prescreening for tailoring treatment in clinical trials. Annals of Oncology. 32. S1346–S1348. 1 indexed citations

16.

Saavedra, Omar, María Vieito, Guzmán Alonso, et al.. (2021). 1623P Phase I clinical trials (CT) forge on despite COVID-19. Annals of Oncology. 32. S1153–S1154. 1 indexed citations

17.

Drilon, Alexander, Oliver Gautschi, Benjamin Besse, et al.. (2021). Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 39(15_suppl). 9032–9032. 1 indexed citations

18.

Besse, Benjamin, Alexander Drilon, Benjamin Solomon, et al.. (2021). Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 39(15_suppl). 9065–9065. 10 indexed citations

19.

Dordal, M T, et al.. (2020). Kounis Syndrome due to Urapidil. Journal of Investigational Allergology and Clinical Immunology. 31(4). 338–340. 4 indexed citations

20.

Casal, José, et al.. (2009). Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. Journal of Clinical Oncology. 27(15_suppl). 7537–7537. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact